20-year experience with intraoperative high-dose-rate brachytherapy for pediatric sarcoma: Outcomes, toxicity, and practice recommendations Academic Article uri icon

Overview

MeSH Major

  • Brachytherapy
  • Sarcoma

abstract

  • HDR-IORT is a well-tolerated component of multimodality therapy for pediatric sarcoma, allowing additional local treatment while reducing external beam exposure. Taking clinical considerations into account, doses between 8-12 Gy are appropriate for HDR-IORT in patients ≤ 6 years of age.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2014.06.016

PubMed ID

  • 25304795

Additional Document Info

start page

  • 362

end page

  • 8

volume

  • 90

number

  • 2